Dr. Gary H. Gibbons, director of the NHLBI, and Dr. George Mensah, director of NHLBI’s Center for Translational Research and Implementation Science, co-authoed a study published in the Journal of the American Heart Association. The study examined the factors existing at the state level that may influence cardiovascular health outcomes.
NHLBI Director Dr. Gary H. Gibbons recently spoke to medical reporters about the future of individualized medicine and highlighted the role the National Institutes of Health is poised to play in moving this field forward.
Gary Gibbons will be the next Director of the National Heart, Lung, and Blood Institute (NHLBI). The selection of Gibbons was announced today by the National Institutes of Health Director Francis Collins. Gibbons is the founder and current director of the Cardiovascular Research Institute, chairperson of the Department of Physiology, and professor of physiology and medicine at the Morehouse School of Medicine in Atlanta.
The discovery of a rare genetic mutation and of two women with dazzingly low LDL cholesterol levels who carry the mutation has set off one of the greatest medical chases ever. NHLBI Director Dr. Gary H. Gibbons said thousands of people could be candidates for any treatments that result from this work.
Read about research that is illuminating the molecular mechanisms that can cascade into debilitating heart disease.
In this Wall Street Journal article Gary H. Gibbons, M.D., director of the NIH's National Heart, Lung, and Blood Institute (NHLBI), and NHLBI grantee Paul Ridker, M.D., director of the center for cardiovascular-disease prevention at Brigham and Women's Hospital in Boston, discuss the launch of the NHLBI-supported cardiovascular inflammation reduction trial (CIRT) that will test if treating inflammation can cut the risk of a heart attack or stroke in high-risk individuals.
On Apr. 5, NIH director Dr. Francis Collins announced the selection of Dr. Gary H. Gibbons as the new director of the NHLBI.
The NHLBI has a long history of supporting highly productive and pivotal research that has translated into new therapies and improved management for chronic lung diseases. To date, our greatest successes have derived from research focused on the treatment of existing diseases in symptomatic patients, and there has been less research attention on primary prevention of lung diseases. We are intrigued by the promise of new insights into chronic lung disease coming from continuing advances in genetics, the blossoming field of reparative biology, and the applications of new imaging and “omic” technologies in well-characterized patients and populations. These scientific advances embolden us to envision a future in which we challenge the prevailing concept of “chronic lung disease” and contemplate the development of preventive strategies that will preempt the progression to lung disease and/or promote its “remission” toward normal lung physiology and respiratory health.
Gibbons, a leader in work related to cardiovascular health of minority populations, has earned 15 NHLBI-supported grants in the last 15 years and has served on the institute's advisory council since 2009. In an interview with Science Insider, Gibbons said he aims to ensure "that NHLBI continues its legacy of doing discovery science that advances public health."
"The globally recognized research and training supported by the NHLBI continues to advance biomedical knowledge in fields related to heart, lung, and blood diseases," Gibbons said. "I look forward to working with the institute staff and with the many researchers supported by the Institute to foster multi-disciplinary approaches to improve disease prevention, diagnosis, and treatment that will advance the health of all Americans."